Insights on the disruption of glucose metabolism and hepatic insulin resistance induced by hepatitis C virus

Abstract

Hepatitis C virus (HCV) is still considered as a major public health problem because in 2015 around 71 million people were chronically infected worldwide. It is important to note that chronic HCV infection is a systemic disease that is associated with diverse extrahepatic disorders including insulin resistance and type 2 diabetes mellitus. The discovery of new direct-acting antiviral agents (DAAs) has become a huge advance in the treatment of HCV infection. The complex interplay between HCV and glucose metabolic pathways remains to be fully elucidated, but it is becoming clearer that elimination of chronic HCV infection halts the progression of liver disease, but more evidence is still needed to better understand how successful antiviral treatment influences insulin resistance and other abnormalities of glucose metabolism linked to HCV infection. This review provides a comprehensive overview of the glucose metabolism disturbances related to chronic HCV infection, highlighting the new insights into the molecular basis of insulin resistance induced by HCV and the mechanisms underlying the reversion of this metabolic disorder by DAAs.

Keywords

Hepatitis C virus / glucose metabolism / type 2 diabetes mellitus / insulin resistance / direct-acting antiviral

References

[1] Global hepatitis report 2017: web Annex B: WHO estimates of the prevalence and incidence of hepatitis C virus infection by WHO region, 2015. Available from: https://apps.who.int/iris/handle/10665/277005 [Last accessed on 14 Mar 2022]

[2] BorgiaSM,ParhyB.Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes.J Infect Dis2018;218:1722-9

[3] GowerE,BlachS,RazaviH.Global epidemiology and genotype distribution of the hepatitis C virus infection.J Hepatol2014;61:S45-57

[4] PoynardT,LeeSS.Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.Lancet1998;352:1426-32

[5] FriedMW,ReddyKR.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.N Engl J Med2002;347:975-82

[6] HézodeC.Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice.Liver Int2012;32 Suppl 1:32-8

[7] Leuw P, Stephan C. Protease inhibitors for the treatment of hepatitis C virus infection.GMS Infect Dis2017;5:Doc08 PMCID:PMC6301719

[8] HerbstDA Jr.Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection.Expert Opin Investig Drugs2013;22:527-36

[9] Rodriguez-TorresM,KowdleyKV.Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.J Hepatol2013;58:663-8

[10] LawitzE,WylesD.Sofosbuvir for previously untreated chronic hepatitis C infection.N Engl J Med2013;368:1878-87

[11] SulkowskiMS,LalezariJ.PHOTON-1 InvestigatorsSofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.JAMA2014;312:353-61 PMCID:PMC4997358

[12] ZeuzemS,WangS.Glecaprevir-Pibrentasvir for 8 or 12 weeks in HCV Genotype 1 or 3 infection.N Engl J Med2018;378:354-69

[13] RyuJK,HongSJ.Association of chronic hepatitis C virus infection and diabetes mellitus in Korean patients.Korean J Intern Med2001;16:18-23 PMCID:PMC4531698

[14] SkowrońskiM,JuszczykJ.Hepatitis C virus infection: evidence for an association with type 2 diabetes.Diabetes Care2006;29:750; author reply 751

[15] AhmedN,NaveedAK.Effect of HCV on fasting glucose, fasting insulin and peripheral insulin resistance in first 5 years of infection.J Pak Med Assoc2016;66:140-2

[16] ChaudhariR,SainuA.Metabolic complications of hepatitis C virus infection.World J Gastroenterol2021;27:1267-82 PMCID:PMC8015302

[17] GastaldiG,ClémentS.Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: a review.J Adv Res2017;8:149-59 PMCID:PMC5272937

[18] WangCC,KaoJH.Systematic review: chronic viral hepatitis and metabolic derangement.Aliment Pharmacol Ther2020;51:216-30

[19] AmbachewS,GeremewD,MelkuM.Prevalence of type 2 diabetes mellitus among hepatitis C virus-infected patients: a protocol for systematic review and meta-analysis.Syst Rev2019;8:60 PMCID:PMC6388482

[20] AllisonME,PalmerCR.Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population.J Hepatol1994;21:1135-9

[21] MehtaSH,StrathdeeSA.Hepatitis C virus infection and incident type 2 diabetes.Hepatology2003;38:50-6

[22] CacoubP,BédossaP.Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study.Antivir Ther2009;14:839-45

[23] El-ZayadiAR.Hepatitis C virus induced insulin resistance impairs response to anti viral therapy.World J Gastroenterol2012;18:212-24 PMCID:PMC3261538

[24] Romero-GómezM,AndradeRJ.Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.Gastroenterology2005;128:636-41

[25] KawaguchiT,TaniguchiE.Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2.Am J Gastroenterol2007;102:570-6

[26] KhattabMA,ShatatM.Changes in adipocytokines and insulin sensitivity during and after antiviral therapy for hepatitis C genotype 4.J Gastrointestin Liver Dis2012;21:59-65

[27] Delgado-BorregoA,NegreB.Halt-C Trial GroupReduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial.Clin Gastroenterol Hepatol2010;8:458-62 PMCID:PMC2856733

[28] ThompsonAJ,ChuangWL.ACHIEVE-1 and ACHIEVE-2/3 Study TeamsViral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3.Gut2012;61:128-34 PMCID:PMC3766841

[29] ChienCH,HuCC,ChienRN.Clearance of hepatitis C virus improves insulin resistance during and after peginterferon and ribavirin therapy.J Interferon Cytokine Res2015;35:981-9

[30] LoIacono O,PettaS.The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C.Aliment Pharmacol Ther2007;25:1181-91

[31] AghemoA,RumiMG.Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.Hepatology2012;56:1681-7

[32] AraseY,SuzukiY.Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.Hepatology2009;49:739-44

[33] Romero-GómezM,AndradeRJ.Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C.J Hepatol2008;48:721-7

[34] SimóR,GenescàJ,HernándezC.Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection.Diabetes Care2006;29:2462-6

[35] BoraieMB,AhmedMO.Effect of direct acting antiviral therapy of Chronic Hepatitis C virus on insulin resistance and Type2 DM in Egyptian patients (prospective study).Diabetes Metab Syndr2019;13:2641-6

[36] CiancioA,BoS.Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents.J Med Virol2018;90:320-7

[37] HumJ,GreenPK.Improvement in glycemic control of type 2 diabetes after successful treatment of hepatitis C virus.Diabetes Care2017;40:1173-80

[38] ZiedHY,El-BendaryAS,HagagRY.Effect of treatment with direct antiviral agents (DAAs) on glycemic control in patients with type 2 diabetes mellitus & hepatitis C virus genotype 4.Diabetes Metab Syndr2020;14:679-82

[39] ReyE,Molina-JiménezF.Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation.Clin Transl Med2021;11:e275 PMCID:PMC7810262

[40] AdinolfiLE,FracanzaniAL.Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: a prospective study.Diabetes Obes Metab2020;22:2408-16

[41] TadaT,ToyodaH.Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy.Aliment Pharmacol Ther2018;47:1012-22

[42] NevolaR,ZeniL.Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct-acting antivirals.JGH Open2020;4:713-21 PMCID:PMC7411572

[43] CarvalhoJR,SerejoF.Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication - comparison of the new direct-acting antiviral agents with the old regimens.Scand J Gastroenterol2018;53:857-63

[44] RussoFP,GambatoM.Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance.J Viral Hepat2020;27:188-94

[45] RibaldoneDG,SaraccoGM.The effect of viral clearance achieved by direct-acting antiviral agents on hepatitis C virus positive patients with type 2 diabetes mellitus: a word of caution after the initial enthusiasm.J Clin Med2020;9:563 PMCID:PMC7074145

[46] SaccoM.The impact of direct-acting antiviral treatment on glycemic homeostasis in patients with chronic hepatitis C.Minerva Gastroenterol (Torino)2021;67:264-72

[47] MastrototaroL.Insulin resistance and insulin sensitizing agents.Metabolism2021;125:154892

[48] BandieraS,ElSaghire H.Hepatitis C virus-induced upregulation of microRNA miR-146a-5p in hepatocytes promotes viral infection and deregulates metabolic pathways associated with liver disease pathogenesis.J Virol2016;90:6387-400 PMCID:PMC4936128

[49] KloverPJ.Hepatocytes: critical for glucose homeostasis.Int J Biochem Cell Biol2004;36:753-8

[50] TaniguchiCM,KahnCR.Critical nodes in signalling pathways: insights into insulin action.Nat Rev Mol Cell Biol2006;7:85-96

[51] LeclercqIA,SchroyenB,GeertsA.Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences.J Hepatol2007;47:142-56

[52] CoppsKD.Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2.Diabetologia2012;55:2565-82 PMCID:PMC4011499

[53] BanerjeeS,Ait-GoughoulteM,RayRB.Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance.J Virol2008;82:2606-12 PMCID:PMC2258989

[54] García-MonzónC,MayoralR.Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C.J Hepatol2011;54:142-52

[55] KawaguchiT,HaradaM.Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3.Am J Pathol2004;165:1499-508 PMCID:PMC1618659

[56] PersicoM,PersicoE.Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy.Hepatology2007;46:1009-15

[57] ZhangW,ChauhanB.FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression.J Biol Chem2006;281:10105-17

[58] DengL,OgawaW.Hepatitis C virus infection promotes hepatic gluconeogenesis through an NS5A-mediated, FoxO1-dependent pathway.J Virol2011;85:8556-68 PMCID:PMC3165828

[59] LeeJ.The role of GSK3 in glucose homeostasis and the development of insulin resistance.Diabetes Res Clin Pract2007;77 Suppl 1:S49-57

[60] HsiehMJ,LiuHY.Hepatitis C virus E2 protein involve in insulin resistance through an impairment of Akt/PKB and GSK3β signaling in hepatocytes.BMC Gastroenterol2012;12:74 PMCID:PMC3464126

[61] SalmeenA,MyersMP,BarfordD.Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B.Molecular Cell2000;6:1401-12

[62] MaehamaT.The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.J Biol Chem1998;273:13375-8

[63] IvaskaJ,ImmonenN,KähäriVM.Integrin alpha 2 beta 1 promotes activation of protein phosphatase 2A and dephosphorylation of Akt and glycogen synthase kinase 3 beta.Mol Cell Biol2002;22:1352-9 PMCID:PMC134683

[64] DuongFH,TripodiM,HeimMH.Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A.Gastroenterology2004;126:263-77

[65] ShlomaiA,BurdelovaEO.The metabolic regulator PGC-1α links hepatitis C virus infection to hepatic insulin resistance.J Hepatol2012;57:867-73

[66] LimTR,OprescuAI.Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure.Clin Endocrinol (Oxf)2019;90:440-8 PMCID:PMC6446809

[67] ChenJ,ZhouY.Chronic hepatitis C virus infection impairs insulin secretion by regulation of p38δ MAPK-dependent exocytosis in pancreatic β-cells.Clinical Science2020;134:529-42

[68] WangQ,WangY,ChenX.Hepatitis C virus induced a novel apoptosis-like death of pancreatic beta cells through a caspase 3-dependent pathway.PLoS One2012;7:e38522 PMCID:PMC3366942